Johnson & Johnson Seeks FDA Approval of Spravato as Monotherapy for Adults with Treatment-Resistant Depression

July 24, 2024

Fluence, Enthea Partner to Expand Access for Ketamine-Assisted Therapy

July 7, 2024

NRx Pharmaceuticals to File Two New-Drug Applications in 2024

July 1, 2024

FDA Approves IND Application for Freedom’s Ketamine-Based Combination Therapy

April 26, 2024

NRx Says New Formulation of IV Ketamine Could Be Delivered Subcutaneously

April 15, 2024

NRx Pharmaceuticals Achieves Data Lock in Phase 2B/3 Trial of NRX-101

April 10, 2024